3 studies found for:    23724913 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements
Conditions: Non-small Cell Lung Cancer;   Anaplastic Lymphoma Kinase Gene Mutation
Intervention:
2 Recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
3 Completed
Has Results
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066;   Drug: Pemetrexed;   Drug: Docetaxel

Indicates status has not been verified in more than two years